BeiGene Deferred Long Term Liab vs Net Working Capital Analysis
BGNE Stock | USD 148.85 5.40 3.50% |
BeiGene financial indicator trend analysis is way more than just evaluating BeiGene prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BeiGene is a good investment. Please check the relationship between BeiGene Deferred Long Term Liab and its Net Working Capital accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BeiGene. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade BeiGene Stock refer to our How to Trade BeiGene Stock guide.
Deferred Long Term Liab vs Net Working Capital
Deferred Long Term Liab vs Net Working Capital Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BeiGene Deferred Long Term Liab account and Net Working Capital. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between BeiGene's Deferred Long Term Liab and Net Working Capital is 0.48. Overlapping area represents the amount of variation of Deferred Long Term Liab that can explain the historical movement of Net Working Capital in the same time period over historical financial statements of BeiGene, assuming nothing else is changed. The correlation between historical values of BeiGene's Deferred Long Term Liab and Net Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Deferred Long Term Liab of BeiGene are associated (or correlated) with its Net Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Working Capital has no effect on the direction of Deferred Long Term Liab i.e., BeiGene's Deferred Long Term Liab and Net Working Capital go up and down completely randomly.
Correlation Coefficient | 0.48 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Deferred Long Term Liab
Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.Net Working Capital
Most indicators from BeiGene's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BeiGene current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BeiGene. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade BeiGene Stock refer to our How to Trade BeiGene Stock guide.At present, BeiGene's Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 17.4 B, whereas Sales General And Administrative To Revenue is forecasted to decline to 0.84.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 15.8M | 52.5M | 37.4M | 39.2M | Depreciation And Amortization | 750K | 751K | 87.7M | 92.1M |
BeiGene fundamental ratios Correlations
Click cells to compare fundamentals
BeiGene Account Relationship Matchups
High Positive Relationship
High Negative Relationship
BeiGene fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.6B | 5.6B | 8.6B | 6.4B | 5.8B | 3.2B | |
Short Long Term Debt Total | 277.3M | 562.0M | 694.6M | 891.1M | 930.2M | 976.7M | |
Other Current Liab | 152.7M | 127.8M | 480.0M | 114.3M | 784.4M | 823.6M | |
Total Current Liabilities | 286.0M | 1.1B | 1.6B | 1.0B | 1.8B | 1.9B | |
Total Stockholder Equity | 978.4M | 3.9B | 6.2B | 4.4B | 3.5B | 2.2B | |
Other Liab | 57.1M | 443.3M | 562.5M | 283.7M | 326.3M | 342.6M | |
Net Tangible Assets | 956.3M | 3.9B | 6.2B | 4.3B | 5.0B | 5.2B | |
Property Plant And Equipment Net | 313.1M | 446.3M | 686.7M | 845.9M | 1.4B | 1.5B | |
Net Debt | (340.7M) | (820.0M) | (3.7B) | (3.0B) | (2.3B) | (2.1B) | |
Retained Earnings | (2.0B) | (3.6B) | (5.0B) | (7.1B) | (8.0B) | (7.6B) | |
Accounts Payable | 122.5M | 232.0M | 262.4M | 294.8M | 315.1M | 330.9M | |
Cash | 618.0M | 1.4B | 4.4B | 3.9B | 3.2B | 3.3B | |
Non Current Assets Total | 439.6M | 640.1M | 1.0B | 845.9M | 1.6B | 1.7B | |
Non Currrent Assets Other | 2.5M | 24.6M | 30.7M | (186.5M) | (18.7M) | (17.8M) | |
Other Assets | 108.7M | 186.8M | 8.6B | 819.9M | 2.0 | 1.9 | |
Long Term Debt | 240.7M | 183.6M | 202.1M | 209.1M | 197.6M | 143.1M | |
Cash And Short Term Investments | 985.5M | 4.7B | 6.6B | 4.5B | 3.2B | 2.3B | |
Common Stock Total Equity | 77K | 79K | 118K | 133K | 153.0K | 160.6K | |
Common Stock Shares Outstanding | 60.1M | 83.5M | 92.8M | 103.1M | 104.4M | 72.1M | |
Short Term Investments | 364.7M | 3.3B | 2.2B | 665.3M | 2.6M | 2.5M | |
Liabilities And Stockholders Equity | 1.6B | 5.6B | 8.6B | 6.4B | 5.8B | 3.2B | |
Non Current Liabilities Total | 347.9M | 656.3M | 803.4M | 977.9M | 423.6M | 372.9M | |
Other Current Assets | 85.8M | 133.0M | 246.2M | 190.9M | 205.5M | 215.8M | |
Other Stockholder Equity | 2.9B | 7.4B | 11.2B | 11.5B | 11.6B | 12.2B | |
Total Liab | 633.9M | 1.7B | 2.4B | 2.0B | 2.2B | 2.3B | |
Property Plant And Equipment Gross | 324.9M | 399.5M | 811.0M | 1.1B | 1.6B | 1.7B | |
Total Current Assets | 1.2B | 5.0B | 7.6B | 4.7B | 4.2B | 2.6B | |
Accumulated Other Comprehensive Income | (8.0M) | 6.9M | 18.0M | (77.4M) | (99.4M) | (94.5M) | |
Short Term Debt | 10.8M | 348.9M | 449.5M | 353.0M | 710.3M | 745.8M | |
Common Stock | 79K | 118K | 133K | 135K | 155.3K | 83.2K | |
Property Plant Equipment | 324.9M | 357.7M | 587.6M | 955.9M | 1.1B | 1.2B | |
Deferred Long Term Liab | 11.1M | 10.5M | 10.8M | 14.2M | 16.3M | 10.1M | |
Long Term Debt Total | 189.7M | 240.7M | 183.6M | 202.1M | 232.4M | 156.4M | |
Capital Surpluse | 2.7B | 2.9B | 7.4B | 11.2B | 12.9B | 13.5B | |
Net Receivables | 72.8M | 79.7M | 500.2M | 173.2M | 395.9M | 415.7M | |
Retained Earnings Total Equity | (1.0B) | (2.0B) | (3.6B) | (5.0B) | (4.5B) | (4.2B) | |
Inventory | 28.6M | 89.3M | 242.6M | 282.3M | 416.1M | 436.9M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether BeiGene is a strong investment it is important to analyze BeiGene's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact BeiGene's future performance. For an informed investment choice regarding BeiGene Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BeiGene. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade BeiGene Stock refer to our How to Trade BeiGene Stock guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Complementary Tools for BeiGene Stock analysis
When running BeiGene's price analysis, check to measure BeiGene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BeiGene is operating at the current time. Most of BeiGene's value examination focuses on studying past and present price action to predict the probability of BeiGene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BeiGene's price. Additionally, you may evaluate how the addition of BeiGene to your portfolios can decrease your overall portfolio volatility.
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing |
Is BeiGene's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BeiGene. If investors know BeiGene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BeiGene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.56) | Revenue Per Share 26.458 | Quarterly Revenue Growth 0.679 | Return On Assets (0.12) | Return On Equity (0.21) |
The market value of BeiGene is measured differently than its book value, which is the value of BeiGene that is recorded on the company's balance sheet. Investors also form their own opinion of BeiGene's value that differs from its market value or its book value, called intrinsic value, which is BeiGene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BeiGene's market value can be influenced by many factors that don't directly affect BeiGene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BeiGene's value and its price as these two are different measures arrived at by different means. Investors typically determine if BeiGene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BeiGene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.